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Abstract
Intradialytic hypotension (IH) is a frequent complication of hemodialysis (HD) and is associated
with increased patient mortality and cardiovascular events. We studied IH to determine its
variability, correlates, and clinical impact in 13 outpatient HD facilities. Blood pressure was
captured by machine download. IH was deﬁned as >30 mmHg decrease in systolic blood
pressure to <90 mmHg. Risk factors were assessed by logistic regression and hospitalization by
Poisson regression. Time to death and ﬁrst hospitalization were assessed using Kaplan–Meier
analysis in patients completing >20 HD treatments. We studied IH in 44,801 treatments (Tx) in
1137 patients. IH was frequent (17.2% of treatments) and highly variable by patient (0–100% Tx)
and dialysis facility (11.1–25.8% Tx). 25.1% of patients had no IH (0% Tx) and 16.2% had IH on
>35% Tx. Increased IH frequency was associated with age, female gender, diabetes, Hispanic
origin, longer end stage renal disease vintage, higher body mass index, higher ultraﬁltration
volume, the second and third weekly Tx, lower pre-HD systolic blood pressure, higher difference
between prescribed and achieved post-HD weight, and higher dialysate temperature. Dialysis
facility was an independent predictor of IH frequency. Patients with >35% IH treatments had
poorer survival (P = 0.036), and more frequent and longer hospitalization (P = 0.04, P = 0.002,
respectively) than patients without IH. In conclusion, IH frequency was highly variable,
associated with individual facilities, patient and treatment characteristics, and correlated with
mortality and hospitalization. Identifying practice patterns associated with IH coupled with
routine reporting of IH will facilitate medical management and may result in the prevention of
IH, decreased mortality, and decreased hospitalization.
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INTRODUCTION
Intradialytic hypotension (IH) is reported to occur during
approximately 5% to 30% of hemodialysis (HD) treat-
ments (Tx)1–4 and has been associated with increased
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patient mortality, access failure, and cardiovascular
events.5–9 Despite this significant impact, IH is not rou-
tinely reported or aggregated in US HD facilities. This lack
of categorized reporting makes it difficult to assess the
overall frequency and impact of IH and may hinder
routine medical management. Investigations of IH etiol-
ogy have primarily focused on the patient factors associ-
ated with the development of hemodynamic instability,
blood pressure (BP) variability, and specific interventions
to prevent and treat IH.10–18 Despite the multiplicity of
reports, the majority of studies reflect a relatively limited
number of HD treatments in a small number of dialysis
facilities and do not provide insight into the overall inci-
dence of IH in the broader HD population. Additionally,
there is a paucity of data regarding the variation in IH
frequency in individual patients or between dialysis facili-
ties. The purpose of this study was to determine the
variability of IH in individual patients and outpatient
dialysis facilities, the patient and treatment factors associ-
ated with IH, and the impact of IH on patient outcomes
including hospitalization and mortality.
METHODS
We prospectively evaluated the epidemiology of IH in 13
outpatient Renal Research Institute (RRI) HD facilities in
five US states (New York 4, Connecticut 3, Michigan 2,
Illinois 1, North Carolina 3) between March 2011 and July
2012. The data collection was part of an ongoing quality
improvement initiative with data feedback to the patients’
caregivers as part of their normal clinical care. These
activities are covered under patients’ informed consent for
treatment and do not qualify as “human research.”
IH was defined as an intradialytic decrease in systolic
BP (SBP) by more than 30 mmHg to a level of less than
90 mmHg. Multiple episodes of IH during the same HD
treatment were considered as one IH episode, and the HD
treatment was considered to have had an IH event (IH
treatment). BP was measured approximately every 30
minutes during dialysis, captured by direct machine
download (iCare system, Fresenius Medical Care NA,
Waltham, MA, USA) and stored in a database. Patient
demographics, treatment parameters, laboratory data and
clinical outcomes were obtained from the RRI clinical data
warehouse. All treatments with available intradialytic BP
data were included for data analysis.
Statistical analysis was performed using SAS 9.3 (SAS
Institute Inc, Cary, NC). Mean, standard deviation and
95% confidence intervals were calculated for continuous
variables; frequency, 95% confidence intervals and
percent were calculated for categorical variables. Con-
tinuous variables were compared by Student t test
between groups. Predictors of IH were investigated with
logistic regression. We built both unadjusted and
adjusted models; for the latter we employed a general-
ized form of mixed effects models with patient-specific
random effects. This adjustment takes into account the
intra-patient variability in patient parameters. Time to
death and time to first hospitalization were modeled by
Kaplan–Meier analysis. For time to event analysis, we
analyzed up to 7 months of follow-up and included only
patients with more than 20 recorded treatments. Unad-
justed Poisson regression was used to compare total
number of hospital admissions and number of hospital
days. Further, relationships between IH, and time to
death and first hospitalization were evaluated using Cox
proportional hazard model adjusted for risk factors for
IH, which were significant in the aforementioned logistic
regression. Please note: this analysis did not include
some lab variables such as hemoglobin, serum sodium,
serum K, and albumen that have been reported associ-
ated with IH. Significance was defined as a two-sided P
value < 0.05.
RESULTS
We studied 44,801 treatments in a total of 1137 patients
as part of an ongoing quality improvement initiative.
Patient demographics and treatment parameters are
shown in Table 1. IH was common (present in 17.2%
of all treatments) and was highly variable by patient
(between 0% and 100% of all treatments), facility (11.1–
25.8% of all treatments) and calendar treatment date (6.8–
26.9% of all treatments on a specific calendar date i.e.,
mm/dd/yyyy). The majority of patients (75.1%) had one
or more episodes of IH (facility range: 63.0% to 84.8% of
facility patients had ≥1 IH episode) and 25.1% of patients
had no episodes of IH (zero frequency: IH on 0% of their
Tx; facility range: 15.2–37.0% patients with 0% IH Tx). In
58.8% of patients, IH occurred in 1% to 35% (moderate
frequency) of their Tx (facility range: 50.4–73.7% patients
with 1–35% IH Tx) and 16.2% of patients had IH on
>35% (high frequency) of their Tx (facility range: 10.3–
33.0% patients with >35% IH Tx) (Table 2).
Over and above patient-related factors, individual
dialysis facilities were independently associated with the
frequency of IH (expressed as % of treatments affected
with IH), both without and with adjustment for patient-
specific random effect (this adjustment takes into account
intra-patient variability in patient parameters; Table 3;
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data without adjustment not shown). Increased risk of IH
was associated with greater age, female gender, presence
of diabetes, Hispanic ethnicity, longer vintage, higher
body mass index (BMI), larger ultrafiltration volume
(UFV), HD on the second and third weekly treatment day,
lower pre-HD SBP, higher difference between prescribed
post-HD weight and actually achieved post weight (calcu-
lated as achieved minus prescribed post-HD weight), and
higher dialysate temperature.
Mortality and hospitalization were analyzed in the
subset of patients (N = 446) with more than 20 recorded
treatments. In this subset, time at risk was computed from
the 20th treatment through December 31, 2012. For the
purpose of this analysis, patients were divided into three
groups based upon IH frequencies: IH in 0% of treatments
(zero frequency), IH in 1% to 35% of treatments (moder-
ate frequency), and IH in >35% of treatments (high fre-
quency). In these 446 patients, mortality was 11.69
deaths per 100 patient-years, hospitalization rate was 1.24
per patient year, and hospitalization days per patient year
was 9.31. Mortality rate, hospital admission rates, and
number of hospital days were significantly higher in
patients with a high frequency of IH (Table 4).
Survival analysis demonstrated a difference in survival
between these three groups (P = 0.045; Figure 1). Patients
with highly frequent IH had the poorest survival
(P = 0.036 compared with patients with without IH (zero
frequency: 0% of treatments). Survival did not differ
between patients with zero and moderate IH frequency
(Table 4). When compared with patients with a high fre-
quency of IH, the adjusted hazard ratio of death was 0.45
(P = 0.20) in patients without IH (zero frequency), and
Table 1 Patient demographics (N = 1137)
Mean
Range between
facilities
Number of patients (N) 1137
Patients (N) per facility 87.5 24–175
Age (years) 61.94 (15.78) 55.4–68.4
Race
Black (%) 51.4 5.3–72.0
White (%) 44.0 8.6–87.1
Hispanic (%) 11.5 0–29.1
Male (%) 53.5 47.1–64.8
Diabetic (%) 56.2 41.8–64.8
Vascular access
AVF (%) 60.7 48.9–79.4
AVG (%) 22.1 7.4–37.5
Catheter (%) 16.4 7.2–27.2
Vintage (years) 4.51 (4.26) 2.95–7.89
BMI (kg/m∧2) 29.0 (8.8) 26.7–32.0
Pre-dialysis SBP (mmHg) 145.5 (20.1) 140–155
Treatments with IH (%) 17.2 11.3–25.8
Sodium gradient (mmol/L)c −1.26 (2.75) 0–2.0
Post weight – EDW (kg) 0.62 (5.1) 0–2.2
Blood flow (mL/min) 428 (46.8) 390–488
Dialysate flow (mL/min) 680.0 (68.9) 629–762
Treatment time (min) 216.3 (29.8) 201–232
spKt/V 1.58 (0.29) 1.47–2.00
Dialysate sodium (mmol/L) 137 (1.1) 136–138
Dialysate potassium (mmol/L) 2.2 (0.35) 2.0–2.4
Dialysate bicarbonate (mmol/L) 35.4 (1.1) 35.0–37.0
Dialysate temperature (Celsius) 36.5 (0.39) 36.2–36.9
AVF = arteriovenous fistula; AVG = arteriovenous graft; BMI = body mass index; EDW = esti-
mated dry weight; IH = intradialytic hypotension; sodium gradient = dialysate sodium-serum
sodium; SBP = systolic blood pressure.
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0.40 (P = 0.08) in patients with moderate IH frequency,
respectively. Hospitalization rate and number of days
spent in the hospital were associated with the frequency of
IH; patients without IH (zero frequency) experienced the
least and shortest hospitalizations (Table 4). When ana-
lyzing the time to first hospitalization, we observed a
significantly shorter time to first hospitalization in patients
with a high frequency IH (P = 0.039) (Figure 2).
Table 2 Intradialytic hypotension (IH) by clinic
Facility
Number of
patients
Number of
treatments
Treatments
with IH (%)
Patients with zero
frequency IH (0%
treatments; %)
Patients with moderate
frequency IH (1–35%
treatments; %)
Patients with high
frequency IH (>35%
treatments; %)
Facility 1 76 2,351 19.1 21.1 63.2 15.8
Facility 2 99 5,537 18.2 15.2 73.7 11.1
Facility 3 24 646 19.0 20.8 62.5 16.7
Facility 4 139 2,803 21.3 30.2 50.4 19.4
Facility 5 54 1,606 23.7 20.4 55.6 24.1
Facility 6 114 7,223 16.2 21.9 65.8 12.3
Facility 7 70 2,634 19.2 20.0 60.0 20.0
Facility 8 69 2,223 19.7 29.0 56.5 14.5
Facility 9 79 2,193 15.1 27.8 58.2 13.9
Facility 10 73 3,364 13.6 37.0 50.7 12.3
Facility 11 68 3,650 19.9 33.8 52.9 13.2
Facility 12 97 2,537 25.8 15.5 51.5 33.0
Facility 13 175 8,034 11.1 28.6 61.1 10.3
Total 1,137 44,801 17.2 25.1 58.8 16.2
Figure 1 Time to death (N = 446). Patients with no (0%) treatments (zero frequency) with intradialytic hypotension (IH) had
longer survival than patients with 1% to 35% (moderate frequency) or with >35% (high frequency) of treatments with IH
(log–rank test; P = 0.045).
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Table 3 Correlates of intradialytic hypotension (IH) by logistic regression
Odds ratio 95% lower CI 95% upper CI P value
Age (years) 1.020 1.014 1.025 <0.0001
Male 0.628 0.541 0.729 <0.0001
Race = White 1.027 0.870 1.212 0.7569
Diabetic 1.375 1.179 1.604 <0.0001
Hispanic 1.391 1.084 1.786 0.0095
Vintage (years) 1.046 1.029 1.062 <0.0001
Catheter 1.170 0.961 1.424 0.1187
BMI (kg/m∧2) 1.013 1.004 1.023 0.0058
Shift
Midday 0.894 0.763 1.047 0.1638
Evening 0.767 0.618 0.951 0.0155
Tx day
Second tx day of the week 1.065 1.004 1.129 0.0356
Third tx day of the week 1.121 1.057 1.189 0.0001
Pre-HD SBP (mmHg) 0.986 0.985 0.988 <0.0001
Ultrafiltration volume (L) 1.309 1.251 1.369 <0.0001
Treatment time (h) 1.080 0.997 1.170 0.0609
Dialysate temperature (Celsius) 1.077 1.011 1.147 0.0209
Achieved minus prescribed post weight (kg) 1.020 1.010 1.031 0.0002
Dialysate sodium (mmol/L) 1.015 0.950 1.084 0.6593
Dialysate potassium (mmol/L) 0.948 0.797 1.127 0.5447
Facility 3 0.889 0.558 1.414 0.6185
Facility 4 1.087 0.819 1.443 0.5651
Facility 5 1.387 1.024 1.879 0.0346
Facility 6 0.906 0.684 1.201 0.493
Facility 7 1.032 0.734 1.450 0.8582
Facility 8 1.031 0.704 1.510 0.8745
Facility 9 0.859 0.606 1.218 0.3934
Facility 10 0.746 0.514 1.081 0.1212
Facility 11 1.078 0.746 1.556 0.6896
Facility 12 1.333 1.007 1.763 0.0446
Facility 13 0.618 0.458 0.833 0.0016
Odds ratio with IH as outcome by treatment with adjustment for random patient effect (for 1 unit change in the predictor variable).
Reference = non-White, non-diabetic, female gender, treated in Facility 1 and 2, treated in the morning, and treated on the first tx day of the
week.
CI = confidence interval.
Table 4 Mortality and hospitalization in patients with ≥20 treatmentsa
Percent of treatments
with IH
Number of
patients
Number of
treatments
Deaths
per 100 pt yrs
Hospital admissions
per pt yr
Hospital days
per pt yr
Zero (0%) 123 2460 8.90 1.10 8.90
Moderate (1–35%) 230 4600 8.9 (P = 0.999) 1.21 (P = 0.47) 9.02 (P = 0.725)
High (>35%) 93 1860 22.4 (P = 0.036) 1.5 (P = 0.04) 10.84 (P = 0.0002)
Total 446 8920 11.69 1.24 9.31
aP values for comparison with patients with low IH frequency (<1% treatments).
IH = intradialytic hypotension.
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DISCUSSION
IH is a frequent complication of HD therapy1–4 with sig-
nificant impact upon patient outcomes.4–9 In this study, IH
was present in 17.2% of all treatments in a large sample
size of 1137 patients with more than 44,800 treatments.
This IH frequency is consistent with previous reports and
emphasizes the clinical significance of the problem of IH.
Shoji et al.6 reported an increased risk in mortality at 2
years in patients with a ≥40-mmHg intradialytic fall in
SBP during one HD treatment. Our data extend this obser-
vation by linking increased hospitalization, hospitalized
days, and mortality to an increased frequency of treat-
ments with IH episodes. Mechanistically, this is also con-
sistent with reports linking IH with myocardial stunning
and adverse outcomes.9
Although the pattern of change in BP during HD has
been previously reported,10 the high variability of IH fre-
quency between facilities, independent of patient char-
acteristics and treatment parameters, has been largely
unappreciated, unreported, and not actively managed.
This variability of IH frequency among outpatient facili-
ties is likely the result of unrecognized variations in
practice patterns and provides a fertile opportunity to
improve patient outcomes. In particular, the facility level
variation of IH frequency, given the association with
adverse patient outcomes,4–9 makes IH an attractive
target for quality improvement initiatives. Numerous
studies have evaluated potential therapeutic interven-
tions to decrease IH. These include use of low-
temperature dialysate,1,13,14 decreasing the ultrafiltration
rate,11,12 longer and more frequent dialysis,11,15 the use of
hemodialfiltration,16 means to lower interdialytic weight
gain,11 high dialysate calcium,19 biofeedback control of
ultrafiltration and infusion20, and adjustment of dialysate
sodium.21 All these studies agree that IH has a high clini-
cal impact and proposed multiple potential therapeutic
interventions. However, IH is not consistently defined,
regularly aggregated, or reported in US outpatient dialy-
sis facilities. This lack of routine reporting limits the
medical management of IH and often leaves attending
nephrologists unaware of the frequency their patients
experience IH. These gaps in reporting offer an enticing
potential avenue to improve patient’s clinical outcomes.
We hypothesize that patient outcomes can be improved
through active and routine reporting, tracking and treat-
ing of IH as part of ongoing clinical care and the facility
quality improvement process. Further studies are neces-
sary to determine whether such active reporting and
routine assessment and management of IH will lead to
improved patient outcomes, decreased hospitalization,
and decreased cost of care.
Figure 2 Time to first hospitalization (N = 446). Patients with >35% (high frequency) of treatments with intradialytic
hypotension (IH) had a shorter time to first hospitalization than patients with 0% (zero frequency) or 1% to 35% (high
frequency) of treatments with IH (log–rank test; P = 0.039).
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Maduell et al.22 recently reported that the incidence of
symptomatic IH was 679.2 episodes per 100 patient-years
(∼4.03% treatments) with online hemodiafiltration and
937.7 episodes per 100 patient-years (∼6.01% treatments)
with HD. Despite different IH definitions (our study did
not capture symptomatic IH vs. non-symptomatic IH),
one can speculate that these markedly lower rates of IH
may contribute to the lower mortality rates for end-stage
renal disease patients reported in Europe when compared
with patients in the United States.23
Most of the individual factors associated with IH fre-
quency (increased age, female gender, diabetes, vintage,
UFV, etc.; Table 3) were anticipated; however, the lower
risk of IH on the first HD day of the week was unexpected.
This may be related to the other adjustments including
UFV in the model. Moreover, dialysis treatment time and
dialysate sodium were not significantly associated with IH
frequency. This lack of significance may relate to the
limited range of treatment times (216.3 ± 29.8 minutes)
and the relatively uniform prescribed dialysate Na
(137 ± 1 mEq/L) in conjunction with multiple other
factors included in the model.
This study is limited by its observational design, and
hence can only provide aggregated measurements and
associations. Moreover, patient symptoms were not col-
lected. This limits comparisons with other studies that
correlate outcomes with symptomatic IH rather than
simply measured decreases in SBP. The associations
between IH and mortality and hospitalization were limited
by the relatively short follow-up time and limited number
of deaths and hospitalizations. Additionally, limiting the
subset analysis of mortality and hospitalization to patients
with more than 20 recorded treatments may introduce
bias because patients had to survive a minimum of 20
treatments, and therefore may have comprised a group of
healthier patients. Lastly, the associations between IH and
mortality and hospitalization may represent markers of
patients’ underlying disease state rather than IH per se as
an independent causative factor.5 However, this limitation
may be mitigated by previous reports linking IH to myo-
cardial stunning; which suggests a potential causative role
for IH in ongoing patient morbidity.9
CONCLUSION
IH is common and highly variable by patient and facility.
The risk of IH was associated with demographic factors,
presence of diabetes, longer dialysis vintage, higher BMI
and UFV, failure to achieve prescribed target post-HD
weight, a lower pre-HD SBP, and higher dialysate tempera-
ture. IH risk was independently associated with specific
dialysis facilities, suggesting an effect of practice patterns.
IH frequency was also associated with mortality and hos-
pitalization. Critical evaluation of facility practice patterns
and potential modifiable risk factors coupled with routine
standardized reporting of IH may reduce the frequency of
IH and decrease patient mortality, hospitalizations, and
cost of care.
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